Every earnings call for IOLCP — management tone, guidance, KPIs and promise tracking, quarter by quarter.
IOLCP · 6 transcripts · Healthcare · latest Q4 FY26IOL Chemicals and Pharmaceuticals Limited has 6 earnings calls on record here, a Healthcare company, most recently Q4 FY26. Each quarter is scored on revenue, margins, guidance delivery and the questions management left unanswered — so the gap between what was promised and what was delivered is easy to read.
FY26 Revenue ₹2,319 cr (+12% YoY); FY26 EBITDA ₹290 cr (+29% YoY); FY26 EBITDA Margin 12.4%. Q4 FY26 Revenue from operations grew 17.4% YoY to INR 619 crores.
Read full transcript & analysisRevenue from Operations (Q3 FY26) ₹580 cr (+11% YoY); EBITDA (Q3 FY26) ₹63 cr (+23% YoY); EBITDA Margin (Q3 FY26) 10.7%. Q3 FY26 Revenue from operations grew 10.9% YoY to INR 580 crores.
Read full transcript & analysisRevenue from Operations ₹568 cr (+8% YoY); EBITDA ₹64 cr (+33% YoY); EBITDA Margin 11.1%. Revenue from operations at INR567.5 crores, up 7.9% YoY.
Read full transcript & analysisRevenue from Operations ₹552 cr (+10% YoY); EBITDA ₹70 cr (+20% YoY); EBITDA Margin 12.4%. Revenue from operations grew 9.8% YoY to ₹552 crores.
Read full transcript & analysisRevenue (Q4 FY25) ₹528 cr (+5% YoY); EBITDA (Q4 FY25) ₹67 cr (+17% YoY); EBITDA Margin (Q4 FY25) 12.7%. Q4 FY25 Revenue from operations grew to INR528 crores, marking a 4.7% YoY growth.
Read full transcript & analysisEBITDA ₹51 cr (−4% YoY); EBITDA Margin 9.7%; Net Profit ₹21 cr (−9% YoY). Q3 FY25 Net Profit at ₹21 crores, up 10.5% QoQ.
Read full transcript & analysis